Findings from the phase III NEJ026 study, presented at the 2018 ASCO Annual Meeting and now published in Lancet Oncology
showed that adding bevacizumab (Avastin) to erlotinib (Tarceva) significantly improved progression-free survival (PFS) versus erlotinib alone in patients with EGFR
-positive, advanced nonsquamous non–small cell lung cancer (NSCLC).
In the phase III FLAURA study, the third-generation EGFR TKI osimertinib (Tagrisso) reduced the risk of progression or death by 54% versus standard therapy with either erlotinib or gefitinib.2 The median PFS was 18.9 months (95% CI, 15.2-21.4) with osimertinib compared with 10.2 months (95% CI, 9.6-11.1) for standard treatment (HR, 0.46; 95% CI, 0.37-0.57; P <.0001).
... to read the full story